急诊科酒精戒断综合征的苯巴比妥治疗:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Web of Science和Embase至2022年5月的文献,纳入2项随机对照试验和6项回顾性队列研究,共1507例患者、2012次酒精戒断综合征治疗就诊,比较苯巴比妥与苯二氮䓬类在急诊科治疗酒精戒断综合征的安全性和有效性。主要结局为ICU入住、住院、出院后再就诊急诊及不良事件。苯巴比妥组与苯二氮䓬类组相比,ICU入住合并相对风险0.92(95%CI 0.54-1.55),住院风险0.98(95%CI 0.89-1.07),任何不良事件风险1.1(95%CI 0.78-1.57);因异质性未能对急诊再就诊进行Meta分析。现有文献未显示苯巴比妥显著减少上述结局。
要点
- 苯巴比妥组与苯二氮䓬类组相比,ICU入住合并相对风险0.92(95%CI 0.54-1.55),未达统计学显著。
- 住院合并相对风险0.98(95%CI 0.89-1.07),两组无显著差异。
- 任何不良事件合并相对风险1.1(95%CI 0.78-1.57),未达统计学显著。
- 因异质性未能对出院后再就诊急诊进行Meta分析。
- 纳入8项研究(2项随机对照试验、6项回顾性队列),总体方法学质量低至中等,偏倚风险中至高等,统计异质性中等。
适用人群与场景
- 急诊科酒精戒断综合征(AWS)患者,数据来自1507例患者共2012次AWS治疗就诊。
- 纳入比较苯巴比妥与苯二氮䓬类治疗的随机试验和队列研究;排除聚焦非AWS疾病的研究。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入8项研究(2项随机对照试验、6项回顾性队列),共1507例患者、2012次AWS治疗就诊;采用随机效应模型。
- 主要结局:苯巴比妥组 vs 苯二氮䓬类组,ICU入住合并相对风险0.92(95%CI 0.54-1.55),住院合并相对风险0.98(95%CI 0.89-1.07),任何不良事件合并相对风险1.1(95%CI 0.78-1.57)。
- 所有研究均纳入不良事件Meta分析,7项纳入住院分析,5项纳入ICU入住分析,3项纳入出院后再就诊急诊分析;因异质性未能对急诊再就诊进行Meta分析。
- 总体方法学质量低至中等,偏倚风险中至高等,统计异质性中等。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入2项随机对照试验和6项回顾性队列研究。
- 总体方法学质量低至中等,偏倚风险中至高等,统计异质性中等。
- 局限:因异质性未能对出院后再就诊急诊进行Meta分析。
对床旁实践的改变
- 现有文献不支持苯巴比妥较苯二氮䓬类显著减少急诊AWS患者的ICU入住、住院、出院后再就诊急诊或不良事件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Despite frequent treatment of alcohol withdrawal syndrome (AWS) in the emergency department (ED), evidence for phenobarbital (PB) as an ED alternative therapy is mixed. We conducted a systematic review and meta-analysis comparing safety and efficacy of PB to benzodiazepines (BZDs) for treatment of AWS in the ED.
METHODS: We searched articles and references published in English in PubMed, Web of Science, and Embase from inception through May 2022. We included randomized trials and cohort studies comparing treatment with PB to BZD controls and excluded studies focused on non-AWS conditions. Review was conducted by two blinded investigators and a third author; eight of 59 (13.6%) abstracts met inclusion criteria for review and meta-analysis using a random-effects model. Treatment superiority was evaluated through utilization, pharmacologic, and clinical outcomes. Primary outcomes for meta-analysis were the proportion of patients (1) admitted to the intensive care unit (ICU), (2) admitted to the hospital, (3) readmitted to the ED after discharge, and (4) who experienced adverse events.
RESULTS: Eight studies (two randomized controlled trials, six retrospective cohorts) comprised data from 1507 patients in 2012 treatment encounters for AWS. All studies were included in meta-analysis for adverse events, seven for hospital admission, five for ICU admission, and three for readmission to the ED after discharge. Overall methodological quality was low-moderate, risk of bias moderate-high, and statistical heterogeneity moderate. Pooled relative risk of ICU admission for those treated with PB versus BZD was 0.92 (95% confidence interval [CI] 0.54-1.55). Risk for admission to the hospital was 0.98 (95% CI 0.89-1.07) and for any adverse event was 1.1 (95% CI 0.78-1.57); heterogeneity prevented meta-analysis for ED readmission.
CONCLUSIONS: The current literature base does not show that treatment with PB significantly reduces ICU admissions, hospital admissions, ED readmissions, or adverse events in ED patients with AWS compared with BZDs alone.
参考来源
- Lee CM, Dillon DG, Tahir PM, et al. Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis. Acad Emerg Med. 2024. PMID: 37923363. doi:10.1111/acem.14825
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。